Category Archives: Regenerative Medicine

Switzerlandisthe safest country in the world for Covid-19according to a new report. Published by the Deep Knowledge Group (described on its website as a Hong Kong venture-capital firm specialising in regenerative medicine), the report assesses the safety level and risk factor for Covid-19 of 200 countries,based on 130 parameters.

Switzerland topped the list with a cumulative score of 752, thanks to factors like an efficient quarantining programme, and effective monitoring, detection and treatment of the virus, preventing an overburdening of the countrys healthcare system.

The report says that Switzerlands ranking is largely due to a continuing decline in its rate of infection spread and mortality, and key factors that put it in a better position to maintain a healthy post-pandemic economy.

Switzerlands economy was also a big factor in achieving the top spot. The report claims that a low level of state debt and a reputation as the major economic and financial epicenter of Europe gives Switzerland a high degree of economic resilience to the financial effects of the pandemic.

Germany was ranked as the second-safest country, and Israel was third, after being named the safest country in a previous edition of the report. The UK was ranked at 68, and the United States at 58.

You can read the full report on Deep Knowledge Groups website.

With most lockdown measures now eased, the Swiss Government announced last week that it would lift entry restrictions and reopen its borders. From June 15, all countries from the European Union, the EU Free Trade Association (Iceland, Liechtenstein and Norway) and the UK will be able to travel to Switzerland.

Continued here:
Switzerland named as the safest country in the world for Covid-19 - Time Out

With this certification, Proteintechs HumanKine Human cell-expressed cytokines and growth factors are now available in GMP-compliant versions for use in clinical trials and commercial manufacturing.

Cytokines and growth factors are critical components to cell and gene therapies. Unlike traditional pharmacologics, cell and gene therapies require the expansion and maintenance of living cells. Cytokines and growth factors coordinate and sustain these processes.

With the rise in clinical trials, there is not only a greater demand for GMP-compliant proteins, but also a demand for safer and more active proteins. Besides being xeno-free and free of animal-derived components, Proteintechs HumanKine Human cell-expressed proteins are produced with native folding, glycosylation, and processing. These properties result in higher efficacy and stability than proteins produced using other systems.

Jeff Lee, Chief Operating Officer at Proteintech, said, It is exciting to have our certification completed in less than 10 months after opening. The timing is great, as it aligns with the completion of several of our product validations.

Deepa Shankar, Chief Scientific Officer at Proteintech, commented, The advances in cell and gene therapy and regenerative medicine have been astounding. As these therapies scale up, the need for quality reagents is more significant than ever. By investing in a new GMP facility and the quality systems to ensure GMP-compliance and ISO 13485 certification, we at Proteintech aim to meet this demand with our suite of GMP grade Human-expressed, well-characterized bioactive proteins.

Proteintech has launched four GMP grade cytokines and has many more planned for launch later this year.

See the article here:
Proteintech announces ISO 13485 Certification for Its HumanKine Human Cell-expressed Cytokines and Growth Factors - The Scientist

Washington, DC, May 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced that it will be holding its annual Legislative Fly-In today. This event, which has been remodeled to take place virtually, enables ARM members to advocate on Capitol Hill for legislative support of gene and cellular therapies and other regenerative medicines.

More than 120 ARM members are participating in the event, making this year ARMs largest Fly-In to date. Participants will form 24 state delegations to meet with Members of Congress via video calls and teleconferencing systems. The meetings will focus onthe immense near-term potential of gene and cell therapies and the need for legislation that supports patient access to these life-saving treatments.

Specifically, Fly-In participants will be asking Members of Congress to remove legislative barriers to the adoption of value-based payment models for gene and cell therapies. These therapies, which can provide a durable and potentially curative therapeutic effect, often with only a single administration, provide a profound benefit to patients and may result incost-savings to the healthcare systemin the medium to long term. However, existing reimbursement mechanisms have difficulty absorbing the upfront cost of these therapies.

To address these challenges, ARM works with its members and policymakers to promote the adoption of innovative payment models for regenerative medicines. These models include annuities, which would allow payors to amortize the cost of therapies over a longer period of time, as well as performance-based models, which tie the payment for therapies to predetermined health outcomes.

For more information on the event or ARMs legislative goals, please contact Kaitlyn (Donaldson) Dupont atkdonaldson@alliancerm.org.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors, and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Kaitlyn (Donaldson) Dupont8037278346kdonaldson@alliancerm.org

Excerpt from:
The Alliance for Regenerative Medicine Announces 2020 Virtual Fly-In, Connecting Sector Stakeholders with Congressional Representatives Amidst the...

By SAM STALL Indianapolis Business JournalINDIANAPOLIS (AP) A dime-size nanochip developed by a world-renowned researcher who recently relocated to Indianapolis could help transform the practice of medicine. It could also turn Indianapolis into a manufacturing and research hub for radically new disease and trauma treatment techniques.

It all began in August 2018, when Chandan Sen, one of the worlds leading experts in the nascent field of regenerative medicine, moved his lab from Ohio State University to the Indiana University School of Medicine. He brought along a team of about 30 researchers and $10 million in research grants, and now serves, among a myriad of other positions, as director of the newly formed Indiana Center for Regenerative Medicine and Engineering, to which IU pledged $20 million over its first five years.IU recruited Sen away from Ohio State in part because of its desire not just to promote academic research in his field but also to help develop practical, commercial products and uses for his breakthroughs.A scientist prefers to be in the lab and keep on making more discoveries, said Sen, 53.But I thought that, unless we participate in the workforce development process and the commercialization process, I dont think that the businesspeople would be ready to do it all by themselves. Because its such a nascent field.

Its definitely new and its potential sounds like the stuff of science fiction.Regenerative medicine, as its name hints, seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.For instance, instead of giving a diabetic a lifetimes worth of insulin injections, some of his skin cells could be altered to produce insulin, curing him. Such techniques might also be used for everything from creating lab-grown replacement organs to, someday, regenerating severed limbs.Regenerative medicine offers a form of medicine that is neither a pill nor a device, Sen said.It is a completely new platform, where you dont necessarily depend on any given drug, but are instead modifying bodily functions.Sen and his teams signal contribution to the field is a technique theyve dubbed tissue nanotransfection, or TNT. Put simply, it uses a nanotechnology-based chip infused with a special biological cargo that, when applied to the skin and given a brief electrical charge, can convert run-of-the-mill skin cells into other cell types. Potentially, the technique could be used for everything from regrowing blood vessels in burn-damaged tissue to creating insulin-secreting cells that could cure diabetics.

Obviously, such applications are still down the road a ways. But the technology is far enough along that some products are already making it to market and investors, entrepreneurs and established companies are sniffing around for opportunities. According to the Alliance for Regenerative Medicine, more than 1,000 clinical trials worldwide are using regenerative medicine technologies.Thousands of patients are already benefiting from early commercial products, and we expect that number will grow exponentially over the next few years, said Janet Lambert, the alliances CEO.Lambert predicts that the number of approved gene therapies will double in the next one to two years. Last year, the U.S. Food and Drug Administration predicted it would be approving 10 to 20 cell and gene therapies each year by 2025.These new techniques could do more than just revolutionize medicine. They could also upend the medical industry as we know it. And the IU School of Medicine and Indianapolis could lead the way.There are really only two or three places in the country that did the kind of comprehensive work that Dr. Sens group was doing, said Anantha Shekhar, executive associate dean for research at IU School of Medicine. And they were doing it from the lab all the way to the clinic, where they were already applying those technologies in patients.

So it was very attractive to think of starting with a bang bringing a comprehensive group here and creating a new center.Instead of merely treating chronic conditions, regenerative medicine could end them, once and for all.For instance, consider a car with an oil leak. The traditional medical approach might be to live with the chronic condition by pouring in a fresh quart of oil every few days. The regenerative medicine approach would fix the leak. Its good for the car, good for the cars owner but not necessarily good for the guy who was selling all those quarts of oil.Which is why these new techniques, if they catch on, could cause turmoil in the medical industry.Because regenerative medicine has the potential to durably treat the underlying cause of disease, rather than merely ameliorating the symptoms, this technology has the potential of being extremely disruptive to the current practice of medicine, Lambert said.This has the potential to be hugely disruptive, Sen added, because so much of medicine today relies on huge industrial infrastructures to manage, not cure, chronic diseases and disabilities.

If such disruption comes to pass, the leaders of 16 Tech, a 50-acre innovation district northwest of downtown that aspires to house dozens of medical-related startups and established firms, would love to be its epicenter.The Center for Regenerative Medicine will be one of the tenants of 16 Techs first building, a $30 million, 120,000-square-foot research and office building scheduled to open in June.Regenerative medicine is probably one of the next major waves of medical innovation in the world, 16 Tech CEO Bob Coy said. To have him here doing this work gives Indianapolis and Indiana an opportunity to develop an industrial cluster in regenerative medicine.Coy believes the most momentous early step on that road was the recent establishment by Sen of masters and doctoral programs in regenerative medicine at the IU School of Medicine. Its the first degree of its type in the country, earning IU and Indianapolis the enviable status of first mover.I think, for example, of (Pittsburghs) Carnegie Mellon University, which, back in the late 1960s, created the first college of computer science in the country, Coy said. And now you know Carnegie Mellons reputation in computer science.What isnt in place yet is a state or city program to promote development of a regenerative medicine hub.

We need to start doing that, Coy said. That means putting a lot of the infrastructure in place to support startups that are based on this technology, as well as recruiting companies that want to collaborate with Dr. Sen.In spite of the lack of a coherent recruitment program, Coys phone has started to ring, thanks largely to Sens presence.There have been a few meetings Ive had with people who already have relationships with him, who, when they come to town, have reached out to meet and talk about what were doing at 16 Tech, he said.One of the first 16 Tech startups with designs on the regenerative medicine niche is Sexton Biotechnologies.The company was groomed by Cook Regentec, a division of Bloomington-based Cook Group charged with incubating and accelerating technologies for regenerative medicine and the related field of cell gene therapy.Any products that show promise are either folded into the company, turned into their own divisions or, as in Sextons case, spun off as an independent entity with Cook retaining a financial stake.

Its a measure of the newness of this field that Sextons 17 employees arent working on new medicines, but rather marketing basic tools needed to conduct research. The companys offerings include a vial for storing cell and gene products in liquid nitrogen, and a cell culture growth medium.Theres a ready market for such tailor-made gear, because, for years, researchers in the regenerative medicine field had to make do with jury-rigged equipment.What most of those companies did was repurpose things like tools from the blood banking industry, or tools from bio pharma, said Sean Werner, Sextons president.So thats why a lot of newer companies are starting to build tools explicitly for the industry, as opposed to everybody just having to cobble together stuff that was already out there.

Werner said investors recognize the momentous opportunity in regenerative medicine and are flocking to the field.Its not something you have to explain, he said. Companies and VC groups are trying to get a piece of it.What has investors and medical researchers charged up is the almost unlimited range of potential applications, from healing burns to, perhaps someday, regenerating limbs.I think it would be a huge revolution if were able to, for example, regenerate insulin-secreting cells in children who have become juvenile diabetics or have for whatever reason lost their pancreas, Shekhar said. Those are the kinds of things that will start to change the way we see certain diseases.Lambert predicted that, as the science advances, so will the business case.

While early programs focused primarily on rare genetic diseases and blood cancers, were already seeing the field expand into more common age-related neurological disorders, such as Parkinsons and Alzheimers, she said.I expect this trend to continue in the coming years, greatly increasing the number of patients poised to benefit from these therapies.Werner said regenerative medicine also is seeking advancements in manufacturing technologies that will lower the cost of product development.It all adds up to a huge opportunity the state is well-positioned to seize, Werner believes.Indiana is a perfect place for this kind of thing to really ramp up, he said. Theres no reason we cant lead the field.__Source: Indianapolis Business Journal

Read this article:
IU team pursues breathtaking regenerative medicine advances - Fort Worth Business Press

Now, more than ever, interest in the immune system and its health has breached our collective consciousness, both phycicians and scientist are turning to regenerative medicine as a way to strengthen it. Recent breakthroughs in the field have led to a newly devised program one with a proprietary protocol for strengthening the immune system, furthering a persons ability to fight and prevent disease.

This inaugural training will take place in Washington over the course of two days, during which we will be training a group of five doctors in the latest regenerative medicine techniques. We will go over our traditional program providing physicians with all of the tools they will need to begin incorporating regenerative medicine into their own practice

The International Society for Stem Cell Application is an independent, non-profit organization whose objective is to become the gold standard of regenerative medicine. It accomplishes this through hosting conferences and specialized certification courses, publishing and sharing clinical research, and setting protocols in the field of regenerative medicine. Through this partnership, we are seeking to spread knowledge on the current applications of cellular therapies by building a platform for doctors to discuss and debate the newest advancements in the field. These conferences have been held in dozens of countries, and work to create a global network of regenerative medicine researchers and practitioners.

If youd like to know more information about our program, or the courses that we offer around the world, please check out by visiting our website at: http://www.issca.us

About International Society for Stem Cells Applications

The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.

At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerativemedicine and make it available to benefit patients both nationally and globally.

For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com

Read the original post:
ISSCA to Conduct First Hands On Regenerative Medicine Training after Global Pandemic - PRUnderground

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical Limited (Company) (ASX:AVH) (NASDAQ:RCEL) today announced that management will present virtually at the upcoming Jefferies Virtual Health Conference on Wednesday, June 3, 2020 at 4:30 p.m. EDT.

Authorised for release by the Chief Financial Officer of AVITA Medical Limited.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

Read more:
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference - Business Wire

MarketsandResearch.biz has released a new research report titled Global Regenerative Medicine Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 to its database which presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis, and key drivers. The report encompasses all the prime factors, making this report extremely useful to all the entrants and potential investors in the global Regenerative Medicine market. The data simplifies this study using a series of channels, including data ranging from rudimentary data to meticulously drawn estimates. Key drivers, as well as challenges of the market, are discussed in the report. The report provides an in-depth analysis of the market with current and future trends.

The report further talks about the definition, types, applications, and major players of the Regenerative Medicine market in detail. The report offers thorough knowledge about the opportunities in business, market status& forecast, the possibility of generating revenue, regional market by different end-users as well as types and future forecasts of upcoming years. The report looks at market status (2015-2020), competitive scenario, advantages and disadvantages of different products and different market players, industry development trends and insights (2020-2026), and regional dominant participants.

NOTE: Our final report will be revised to address COVID-19 effects on the specific market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/44907

Below mentioned is the list of few companies engaged in the market: ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter,

On the basis of product types of market: Mono Avalanche Airbags, Dual Avalanche Airbags

The study explores the key applications/end-users of the market: Skiing, Climbing, Hiking, Others

Furthermore, the report includes a deep compilation of the respective industry and a detailed overview of its segmentation. The report offers a fundamental outlook of the global Regenerative Medicine markets present status and size in terms of volume and value. The essential data about the vital geographical regions and primitive players has been summarized in the report. The market has been broken down into various segments, regions, end-uses, and players to provide a clear picture of the present market situation. Segmentation of the market highlights the growth prospects and trends impacting these segments.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/44907/global-regenerative-medicine-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2026

The Geographical Landscape of The Market:

The research offers an analysis of the geographical landscape of the global Regenerative Medicine market, which is divided into regions such as North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). It includes data about several parameters related to the regional contribution. The study provides information regarding the sales generated through each region and the registered market share. Information related to the growth rate during the forecast period is included in the report. According to the report, the industry is projected to generate significant revenue during the forecast period.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Read more:
Global Regenerative Medicine Market Research Report With COVID-19 Update - Cole of Duty

A clinical trial showed the ability of a stem cell-based topical solution to regrow hair in people with male/female pattern baldness.

The results of a clinical trial released today (May 18, 2020) in STEM CELLS Translational Medicinedemonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.

Androgenetic alopecia (AGA) commonly known as male-pattern baldness (female-pattern baldness in women) is a condition caused by genetic, hormonal and environmental factors. It affects an estimated 50 percent of all men and almost as many women older than 50. While it is not a life-threatening condition, AGA can lower a persons self-esteem and psychological well-being. There are a few FDA-approved medications to treat hair loss, but the most effective can have side effects such as loss of libido and erectile dysfunction. Therefore, the search continues for a safer, effective treatment.

Adipose tissue-derived stem cells (ADSCs) secrete several growth hormones that help cells develop and proliferate. According to laboratory and experimental studies, growth factors such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF) and platelet-derived growth factor (PDGF) increase the size of the hair follicle during hair development.

A more enriched adipose-derived stem cells-constituent extract (ADSC-CE) with stem cell proteins is obtained by disruption of the ADSC membrane using a low frequency of ultrasound wave. Credit: AlphaMed Press

Recent studies have shown that ADSCs promote hair growth in both men and women with alopecia. However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in AGA. We aimed to assess the efficacy and tolerability of ADSC-CE in middle-aged patients with AGA in our study, hypothesizing that it is an effective and safe treatment agent, said Sang Yeoup Lee, M.D., Ph.D., of the Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital in South Korea. He led the group of researchers, which also included colleagues from Pusan National University School of Medicine, Pusan National University Yangsan Hospital and T-Stem Co., Ltd.

The team recruited 38 patients (29 men and nine women) with AGA and assigned half to an intervention group that received the ADSC-CE topical solution and half as a control group that received a placebo. Twice daily, each patient applied the ADSC-CE topical solution or placebo to their scalp using their fingers.

At the end of 16 weeks, the group that received the ADSC-CEs had a significant increase in both hair count and follicle diameter, reported the studys senior author, Young Jin Tak, M.D., Ph.D.

Dr. Lee added, Our findings suggest that the application of the ADSC-CE topical solution has enormous potential as an alternative therapeutic strategy for hair regrowth in patients with AGA, by increasing both hair density and thickness while maintaining adequate treatment safety. The next step should be to conduct similar studies with large and diverse populations in order to confirm the beneficial effects of ADSC-CE on hair growth and elucidate the mechanisms responsible for the action of ADSC-CE in humans.

For the millions of people who suffer from male-pattern baldness, this small clinical trial offers hope of a future treatment for hair regrowth, said Anthony Atala, M.D., Editor-in-Chief ofSTEM CELLS Translational Medicineand director of the Wake Forest Institute for Regenerative Medicine. The topical solution created from proteins secreted by stem cells found in fat tissue proves to be both safe and effective. We look forward to further findings that support this work.

###

Reference: A Randomized, Double-blind, Vehicle-Controlled Clinical Study of Hair Regeneration Using Adipose-Derived Stem Cell Constituent Extract in Androgenetic Alopecia by Young Jin Tak, Sang Yeoup Lee, A Ra Cho and Young Sil Kim, 18 May 2020, STEM CELLS Translational Medicine.DOI: 10.1002/sctm.19-0410

AboutSTEM CELLS Translational Medicine:STEM CELLS Translational Medicine(SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals:STEM CELLS, celebrating its 38th year, is the worlds first journal devoted to this fast paced field of research.The Oncologist, also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Go here to read the rest:
New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily

PHOENIX--(BUSINESS WIRE)--BioLab Sciences, a regenerative biotechnology company, today announced a partnership with Red One Medical that will help veterans and active military members access breakthrough wound healing and regenerative medicine.

Red One Medical is private sector innovation partner of Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), it provides advanced medical and pharmaceutical technologies that improve patient care for America's military veterans. BioLab Sciences is working with Red One Medical to distribute regenerative medicine products and MyOwn Skin, a novel biotechnology that can accelerate the healing of severe burns, chronic wounds, diabetic foot ulcers, and other difficult-to-heal wounds.

Nearly one in four veterans has diabetes, and as such, the need for an innovative wound care solution is critical to treat non-healing diabetic ulcersthe leading cause of lower-limb amputations in non-combat veterans.

Were constantly on the lookout for innovative products to speed wound healing in veteran and military hospitals," said Red One Medical CEO and Founder Charles Pollak. "We want our veterans to receive top quality care, and MyOwn Skin takes wound care to the next level by leveraging a patient's own skin to quickly grow skin grafts in a new, non-invasive way."

MyOwn Skin leverages a very small sample of a patient's skin and blood taken through a non-surgical procedure to reproduce three, 100cm2 skin grafts within a week. MyOwn Skin eliminates the need for traditional skin grafts which require surgical procedures to remove large areas of healthy skin from other parts of a patients body, often resulting in additional wounds requiring care and healing time.

We are on a mission to help patients and providers access regenerative medicine products that help the body achieve optimal performance, said BioLab Sciences President and CEO Bob Maguire. As the VAs private sector innovation partner, Red One Medical is in a unique position to help advance the delivery of care to our nations veteran and military patients. This partnership is one step forward in that direction.

Along with MyOwn Skin, which is now one of the most advanced products in Red One Medical's wound care portfolio, the company will also distribute BioLab Sciences amniotic allograft membrane, amniotic liquid allograft and other regenerative products that promote healing for wound, orthopedic, respiratory and ophthalmic care. The products will be available to the DoD and VA health system, which includes more than 9 million veterans at approximately 1,700 facilities.

About BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin, a remarkable biotechnology that leverages a small sample of a patient's own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week. Learn more at http://www.biolabsciences.net/.

About Red One Medical

Red One Medical is a private sector innovation partner of Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals. Red One Medical identifies and delivers advanced medical and pharmaceutical technologies that transform care for Americas military veterans. Located in Savannah, GA, Red One Medical is a CVE-certified Service Disabled Veteran Owned Business (SDVOSB) and SBA-certified Historically Underutilized Business Zone (HUBZone) company. It donates a portion of profits to charities that support veterans, military families and their communities.

Read this article:
BioLab Sciences Partners with Red One Medical to Provide Transformative Wound Healing Products to Veterans and Active Military - Business Wire

The recently published market study by MRRSE highlights the current trends that are expected to influence the dynamics of the Regenerative Medicine market in the upcoming years. The report introspects the supply chain, cost structure, and recent developments pertaining to the Regenerative Medicine market in the report and the impact of the COVID-19 on these facets of the market. Further, the micro and macro-economic factors that are likely to impact the growth of the Regenerative Medicine market are thoroughly studied in the presented market study.

According to the report, the Regenerative Medicine market is expected to grow at a CAGR of ~XX% during the forecast period, 20XX-20XX and attain a value of ~US$ XX by the end of 20XX. The report is a valuable source of information for investors, stakeholders, established and current market players who are vying to improve their footprint in the current Regenerative Medicine market landscape amidst the global pandemic.

Request Sample Report @https://www.mrrse.com/sample/6729?source=atm

Reasons to Trust Our Business Insights

Critical Data in the Regenerative Medicine Market Report

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/6729?source=atm

Regional Assessment

The regional assessment chapter in the report offers an out and out understanding of the potential growth of the Regenerative Medicine market across various geographies such as:

Application Assessment

The presented study ponders over the numerous applications of the Regenerative Medicine and offers a fair assessment of the supply-demand ratio of each application including:

segmented as follows:

Regenerative Medicine (Bone and Joint) Market, by Technology

Regenerative Medicine (Bone and Joint) Market, by Application

Regenerative Medicine (Bone and Joint) Market, by Geography

View original post here:
Impact of COVID-19 Outbreak on Regenerative Medicine Market with Global Innovations, Competitive Analysis, New Business Developments and Top Companies...